Plasma Low-density Lipoprotein Receptor-related Protein 1 Concentration is not Associated with Human Abdominal Aortic Aneurysm Presence  by Moxon, J.V. et al.
Eur J Vasc Endovasc Surg (2015) 50, 466e473Plasma Low-density Lipoprotein Receptor-related Protein 1 Concentration is
not Associated with Human Abdominal Aortic Aneurysm Presence5
J.V. Moxon a, R. Behl-Gilhotra a, S.K. Morton a, S.M. Krishna a, S.W. Seto a,b, E. Biros a, M. Nataatmadja c, M. West c, P.J. Walker d,
P.E. Norman e, J. Golledge a,d,f,*
a Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD 4811, Australia
b National Institute of Complementary Medicine, University of Western Sydney, Campbelltown, NSW 2560, Australia
c The Cardiovascular Research Group, Department of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, QLD 4032, Australia
d School of Medicine, Discipline of Surgery and Centre for Clinical Research, University of Queensland, Herston, QLD 4072, Australia
e School of Surgery, University of Western Australia, Perth, WA 6009, Australia
f Department of Vascular and Endovascular Surgery, The Townsville Hospital, Townsville, QLD 4814, Australia5 Sa
other v
* Cor
QLD 48
E-ma
1078
http:WHAT THIS PAPER ADDS
Polymorphisms within LRP1 have been suggested to contribute to the risk of abdominal aortic aneurysm (AAA).
This study demonstrates that plasma concentrations of low-density lipoprotein receptor-related protein 1 (LRP1)
are similar in men with and without AAA, suggesting that this protein is an unsuitable marker with which to
screen for in at-risk populations. This study conﬁrms that LRP1 expression is reduced in aortic biopsies collected
from patients with AAA compared with nonaneurysmal controls, and demonstrates that inhibition of LRP1
reduces the ability of vascular smooth muscle cells to internalize matrix metalloprotease 9 in vitro. These
ﬁndings suggest that localized LRP1 dysregulation may be important in AAA pathogenesis but is an unsuitable
marker with which to screen at-risk populations.Objective/Background: Recent genetic data suggest that a polymorphism of LRP1 is an independent risk factor
for abdominal aortic aneurysm (AAA). The aims of this study were to assess whether plasma and aortic
concentrations of low-density lipoprotein receptor-related protein 1 (LRP1) are associated with AAA, and to
investigate the possible relevance of LRP1 to AAA pathophysiology.
Methods: Three analyses were conducted. First, plasma LRP1 concentrations were measured in community-
dwelling men with and without AAA (n ¼ 189 and n ¼ 309, respectively) using enzyme-linked immunosorbent
assay. Second, Western blotting analyses were employed to compare the expression of LRP1 protein in aortic
biopsies collected from patients with AAA and nonaneurysmal postmortem donors (n ¼ 6/group). Finally, the
effect of in vitro LRP1 blockade on matrix metalloprotease 9 (MMP9) clearance by vascular smooth muscle cells
was assessed by zymography.
Results: Plasma LRP1 concentrations did not differ between groups of men with and without AAA (median
concentration 4.56 mg/mL [interquartile range {IQR} (3.39e5.96)] and 4.43 mg/mL [IQR 3.44e5.84], respectively;
p ¼ .48), and were not associated with AAA after adjusting for other risk factors (odds ratio 1.10 [95% conﬁdence
interval: 0.91e1.32]; p ¼ 0.35). In contrast, LRP1 expression was approximately 3.4-fold lower in aortic biopsies
recovered from patients with AAA compared with controls (median [IQR] expression 1.72 [0.94e3.14] and 5.91
[4.63e6.94] relative density units, respectively; p < .01). In vitro LRP1 blockade signiﬁcantly reduced the ability
of vascular smooth muscle cells to internalize extracellular MMP9.
Conclusions: These data suggest that aortic but not circulating LRP1 is downregulated in patients with AAA and
indicates a possible role for this protein in clearing an aneurysm-relevant ligand.
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Abdominal aortic aneurysm (AAA) affects approximately 2%
of men and roughly 1% of women aged > 65 years, and
signiﬁcantly increases the risk of mortality through aortic
rupture and associated cardiovascular events.1,2 The aetiology
of AAA remains unclear; however, inﬂammation, extracellular
matrix degeneration, and vascular smoothmuscle cell (VSMC)
loss appear to be important in the pathogenesis.3,4 AAA risk
factors include advanced age, male sex, and smoking.1 A
positive family history roughly doubles the risk of AAA, sug-
gesting that genetic factors are important in the development
of AAA.5,6 A genome-wide association study identiﬁed a
positive association of the rs1466535 major (C) allele within
LRP1 with the presence of AAA (odds ratio [OR]w1.2).7 This
association appeared to be AAA speciﬁc and was maintained
after adjusting for cardiovascular risk factors, leading to the
suggestion that the LRP1 rs1466535 C allelemight signiﬁcantly
contribute to the risk of AAA.8,9 However, this is contradicted
by recent reports of a positive association between AAA and
the LRP1 rs1466535 T (minor) allele in a geographically
distinct patient population.10
Low-density lipoprotein receptor-related protein 1 (LRP1)
is structurally related to the low-density lipoprotein recep-
tor and comprises a 100-amino acid cytoplasmic domain, a
membrane-spanning region, and an extracellular loop with
four ligand-binding regions.11,12 LRP1 is predominantly
expressed by VSMCs and facilitates the internalization and
clearance of bound ligands.12e14 Previous studies suggest
that LRP1 has functions beyond lipid metabolism, and
known LRP1 ligands include growth factors, matrix metal-
loproteases (MMPs), protease inhibitor complexes, and
extracellular matrix components.8,11,12 Conditional LRP1
knockout rodent models demonstrate that LRP1 deﬁciency
results in abnormal VSMC proliferation and migration,
increased extracellular matrix turnover and aneurysm for-
mation within the mesenteric arteries.14e16 Currently, only
one study has directly investigated whether LRP1 expres-
sion is altered in human AAA.17 In this study, Chan et al.
employed Western blotting and immunohistochemistry to
demonstrate signiﬁcant downregulation of the LRP1 protein
in aortic biopsies of Chinese patients with AAA compared
with nonaneurysmal controls. It was hypothesized in the
present study that reduced aortic LRP1 concentrations may
result from release of this protein from the aneurysm wall,
which may increase circulating LRP1 concentrations in pa-
tients with AAA. In this study the association of circulating
and aortic concentrations of LRP1 with AAA were assessed.
The functional role of LRP1 in clearing MMP9 in VSMCs was
also examined in vitro.
MATERIALS AND METHODS
Detailed materials and methods are provided in
Supplementary File 1.
Participants
Samples collected from three Australian cohorts were used:
(i) plasma samples collected from participants of the Healthin Men Study (HIMS); (ii) aortic biopsies from patients un-
dergoing open surgery to repair large AAA; (iii) aortic bi-
opsies from nonaneurysmal heart-beating, brain-dead
organ donors.18 For HIMS participants, an infrarenal aortic
(IRA) diameter of 30e55 mm was deﬁned as a small AAA.
An IRA diameter >55 mm was considered as a large AAA.
Clinical information collected during the HIMS included age,
medical history, and smoking status. For patients undergo-
ing AAA repair, risk factors were recorded as previously
described (Supplementary File 1).19,20 Maximum IRA diam-
eter was measured from axial computed tomography
angiography images as previously described.21 No clinical
information other than age and sex was available for organ
donor participants. In all instances, written informed con-
sent and institutional ethics approval was provided.
Measurement of plasma LRP1
Plasma LRP1 concentrations were measured using a
commercially available enzyme-linked immunosorbent assay
(ELISA) (#E91010Hu, USCN Life Sciences,Wuhan, China). This
ELISA employs antibodies against a soluble extracellular
LRP1 immunogen suggesting suitability for plasma analysis.
Reported inter- and intra-assay variabilities are < 12%.
Owing to limited plasma volumes, single measurements
were taken for each patient as previously described.19,22
In vitro experiments
Human aortic VSMC (CC-2571; Lonza, Walkersville, MD,
USA) were maintained in growth medium in a humidiﬁed
5% CO2 atmosphere at 37
C and passaged when 70e80%
conﬂuent. After ﬁve passages, LRP1-blocking antibodies or
isotype control antibodies (#MA1-27198 and MA5-14453,
respectively; Thermo Fisher Scientiﬁc, Scoresby, Australia)
were added to the culture media at concentrations of
30 mg/mL. Cell culture supernatants were decanted after 24
hours and replaced with media containing 20 ng/mL re-
combinant human MMP9 (#911-MP-010; R&D Systems,
Minneapolis, MN, USA). Cell culture supernatants were
harvested at 24 and 48 hours, and stored at 80 C. Data
presented are from three independent culture experiments.
Protein extraction and Western blotting
Isolation of aortic proteins and Western blotting was per-
formed as previously described.23 Full-thickness human
abdominal aortic samples were homogenized in the pres-
ence of protease inhibitors. Samples (30 mg protein/lane)
were loaded onto a 10% sodium dodecyl sulfateepoly-
acrylamide gel, electrophoresed and transferred onto a
polyvinylidene diﬂuoride membrane. The membrane was
cut at w60 kDa and each half separately blocked with 5%
nonfat dry milk at 4 C overnight. The 60e250-kDa proteins
were incubated with anti-LRP1 antibody (MAB6360; R&D
Systems), while the proteins < 60 kDa were incubated with
anti-b actin antibody (#AB75186; Abcam, Cambridge, UK)
for 1 hour (room temperature). Membranes were washed
and incubated with antimouse horseradish peroixidase-
conjugated (LRP1 blot) or antirabbit (b-actin)-conjugated
Table 1. Clinical characteristics of 498 population-screened men
included in the plasma low-density lipoprotein receptor-related
protein 1 (LRP1) analyses.
Characteristic Men without AAA
(AOD < 30 mm;
n ¼ 309)
Men with AAA
(AOD > 30 mm;
n ¼ 189)
p
IRA diameter
(mm)
19.5 (19.2e20.2) 33.7 (31.7e40.3) <.01
Age (years) 72 (68e75) 72 (68e75) .28
468 J.V. Moxon et al.IgG (#P0447 and P0448, respectively; DakoCytomation,
Glostrup, Denmark) for 1 hour (room temperature). Mem-
branes were washed and proteins visualized with Western
Lightning Chemiluminescence Reagent Plus (Perkin Elmer
Life Sciences, Billerica, MA, USA). The relative density of the
LRP1 band was standardized by dividing by mean b-actin
density for the respective experimental group. Reported
data refer to standardized LRP1 expression.Waist-to-hip
hip ratio
0.95 (0.91e1.00) 0.96 (0.93e1.00) .07
Plasma LRP1
(mg/mL)
4.43 (3.44e5.84) 4.56 (3.39e5.96) .48
Past history, n (%)
Ever smoking 196 (63.4) 163 (86.2) <.01
Hypertension 126 (40.8) 97 (51.3) .02
Dyslipidemia 133 (43.0) 90 (47.6) .32
Diabetes 34 (11.0) 18 (9.5) .60
Stroke 19 (6.1) 17 (9.0) .23
CHD 83 (26.9) 83 (43.9) <.01
Note. Nominal variables are presented as numbers and valid % andGelatin zymography
Five microliters of VSMC culture supernatant was loaded
onto a 10% polyacrylamide gel containing 1 mg/mL gelatin.
Samples were electrophoresed and washed twice in 2.5%
(v/v) Triton X-100. Gels were incubated overnight in 50 mM
Tris-HCl (pH 8.0), 5 mM CaCl2 at 37
C, and stained with
0.5% (w/v) Coomassie Blue R-250 for 30 minutes. Gels were
destained with 40% (v/v) methanol, 10% (v/v) acetic acid,
and 50% (v/v) water in order to visualize protease activity,
and analyzed via densitometry as explained above.compared using the chi-square test. Continuous variables are
presented as median (interquartile range) and compared using
the ManneWhitney U-test. AOD ¼ aortic diameter;
IRA ¼ infrarenal aorta; CHD ¼ coronary heart disease.Statistical analyses
Data were analyzed using SPSS version 21 (IBM, Armonk,
NY, USA) and Prism v.6 (GraphPad Software, La Jolla, CA,
USA). Continuous variables were analyzed using the Manne
Whitney U-test. Nominal variables were assessed using the
chi-square test. Correlations were assessed using Spearman
Rho (r) analyses. The correlation between aortic LRP1
expression and AAA diameter was further assessed in
“leave-one-out” sensitivity analyses. The association of
plasma LRP1 with the presence of AAA was assessed via
binary logistic regression corrected for confounders identi-
ﬁed in univariate analyses. In vitro data comparing three
groups were assessed using one-way analysis of variance
applying Tukey’s post-hoc test for multiple comparisons. p-
values < .05 were considered signiﬁcant.
RESULTS
Plasma LRP1 concentrations are not associated with AAA
LRP1 concentration was measured in plasma collected from
189 men with a small AAA, and 309 nonaneurysmal controls
(total n ¼ 498). Participant characteristics are shown in
Table 1. Participants had similar age and history of dyslipi-
demia, diabetes, and stroke. The prevalence of smoking,
hypertension and coronary heart disease (CHD) were
signiﬁcantly higher in men with AAA. No differences in
plasma LRP1 concentration were observed between the
groups. Median plasma LRP1 concentration was 4.56 mg/mL
(interquartile range [IQR] (3.39e5.96) for men that had AAA
and 4.43 mg/mL (IQR 3.44e5.84) for nonaneurysmal con-
trols (p ¼ .48; Table 1, Fig. 1A). Plasma LRP1 concentrations
did not correlate with IRA diameter when assessing the
whole population (r ¼ 0.06, p ¼ 0.22; Fig. 1B), or the
experimental groups (for men with AAA: r ¼ .06, p ¼ .44;
for controls: r ¼ .05, p ¼ .34, data not shown).
Binary logistic regression was conducted to identify the
major risk factors for AAA in the studied population. Anincrease in plasma LRP1 concentration of w1 SD (2.7 mg/
mL) was not signiﬁcantly associated with the presence of
AAA in unadjusted analyses (OR 1.07, 95% conﬁdence in-
terval [CI] 0.89e1.28; p ¼ .48), or in analyses adjusting for
waist-to-hip ratio, smoking history, hypertension, and CHD
(OR 1.10, 95% CI 0.91e1.32; p ¼ .35) (Supplementary
Table 1). A history of ever having smoked (OR 3.44, 95%
CI 2.12e5.58; p < .01) and CHD (OR 1.94, 95% CI 1.29e
2.91; p < .01) were independent risk factors for AAA in this
population, as previously described (Supplementary
Table 1).19,22Western blot analysis of aortic LRP1 expression
As plasma LRP1 concentrations were similar in patients with
AAA and controls, Western blotting experiments were
conducted to verify whether IRA LRP1 expression was lower
in patients with AAA compared with nonaneurysmal con-
trols (n ¼ 6/group). Patients and controls were sex matched
(67% men/group; p ¼ 1.00). Younger patients with AAA
were speciﬁcally selected for this analysis in order to
minimize age imbalances between the groups, although
patients with AAA were older than organ donors (median
[IQR] age 58.0 years [54.8e66.8] and 45.0 years [34.0e
51.0], respectively; p ¼ .026). Median IRA diameter for the
patients with AAA was 62.8 mm (IQR 57.3e79.2). IRA
measurements were not available for controls. Western
blotting identiﬁed a band atw90 kDa in all samples, which
was selected for analysis as advised by the antibody
manufacturer (Fig. 2A, Supplementary Fig. 1). Standardized
median aortic LRP1 expression was w3.4-fold lower in pa-
tients with AAA than nonaneurysmal controls (median [IQR]
expression 1.72 [0.94e3.14] and 5.91 [4.63e6.94] relative
Figure 1. Plasma low-density lipoprotein receptor-related protein 1 (LRP1) is not associated with the presence of abdominal aortic
aneurysm (AAA). (A) Enzyme-linked immunosorbent assay revealed no difference in circulating LRP1 concentrations in men with AAA
(n ¼ 189) and nonaneurysmal controls (n ¼ 309; ManneWhitney U-test). B) No correlation was seen between plasma LRP1 concentration
and infrarenal aortic diameter. Nonaneurysmal controls are boxed.
Plasma LRP1 Concentration and AAA Presence 469density units [RDU], respectively; p < .01 [Fig. 2B]). No
signiﬁcant correlation between standardized LRP1 expres-
sion and IRA diameter in the patients with AAA was
observed (r ¼ .60, p ¼ .24; Fig. 2C). No signiﬁcant corre-
lation between tissue LRP1 expression and AAA diameter
was observed following leave-one-out sensitivity analysis
(Supplementary Table 2).In vitro LRP1 blockade inhibits VSMC MMP9 clearance
The relevance of LRP1 underexpression to AAA pathology
remains unclear. LRP1 dysfunction has been suggested toFigure 2. Western blot analysis of low-density lipoprotein receptor-
recovered from patients with abdominal aortic aneurysms (AAA) and
infrarenal aortic LRP1 expression in patients with AAA (AAA) and contr
aortic LRP1 expression to be signiﬁcantly lower in patients with AAA th
denote median and interquartile ranges. (C) Standardized LRP1 express
the patients with AAA. Note. RDU ¼ relative density units.promote AAA through inefﬁcient clearance of extracellular
ligands, including proteases.9 The effect of LRP1 blockade
on extracellular clearance of MMP9 by VSMC was assessed
in vitro. VSMC were exposed to LRP1 blocking antibodies,
isotype control IgG, or vehicle for 24 hours, prior to adding
recombinant MMP9. Conditioned media MMP9 activity was
assessed, using gelatin zymography, 24 and 48 hours after
the addition of MMP9 (Supplementary Fig. 2).
After 24 hours, the MMP9 activity of culture superna-
tants was comparable between cells exposed to MMP9 with
anti-LRP1 antibodies, isotype control IgG, or vehicle
(mean  SEM MMP9 activity 3.69  0.50, 3.85  0.26, andrelated protein 1 (LRP1) expression in infrarenal aortic biopsies
nonaneurysmal organ donors. (A) Immunoblot detailing relative
ols (CTRL). (B) Comparisons between groups revealed standardized
an controls. Symbols represent individual samples; horizontal bars
ion did not signiﬁcantly correlate with infrarenal aortic diameter in
470 J.V. Moxon et al.4.58  0.31 RDU, respectively; p ¼ .27 [Fig. 3A]). The MMP9
activity of media from all three groups was signiﬁcantly
greater than negative control cells, which did not receive
recombinant protease (all p < .05; data not shown). After
48 hours, extracellular MMP9 activity differed signiﬁcantly
between VSMC receiving anti-LRP1 antibodies, isotype
control IgG, or vehicle (mean  SEM 11.27  0.44,
8.29  0.45, and 9.80  0.75 RDU, respectively; p ¼ .03
[Fig. 3B]). Between-group comparisons demonstrated that
conditioned media from VSMC receiving LRP1-blocking an-
tibodies exhibited signiﬁcantly higher MMP9 activity than
the control IgG1-exposed cells (mean difference between
groups 2.97, 95% CI 0.53e5.42; p < .05). MMP9 activity
from all three groups remained higher than the negative
controls at this time point (all p-values < .05; data not
shown).DISCUSSION
Recent data suggest that the LRP1 rs1466535 polymorphism
may be a speciﬁc risk factor for AAA.7,9,10 A previous study
has reported that LRP1 expression within the IRA is signif-
icantly lower in patients with AAA compared with organ
donor controls.17 It has been demonstrated that proteins
liberated from the aneurysm wall may enter the blood-
stream and act as potential biomarkers for AAA.24e26
Consequently, it was hypothesized in the present study
that loss of aortic LRP1 from the IRA of AAA patients may be
associated with high circulating LRP1 concentrations, how-
ever plasma LRP1 concentrations were similar in men with
(n ¼ 189) and without AAA (n ¼ 309). Given this ﬁnding,
veriﬁcation of the previous ﬁnding that LRP1 was down-
regulated within the aorta of patients with AAA was
attempted. LRP1 expression was assessed in IRA biopsies
collected from patients with AAA and organ donor controls.
Currently, only one study has reported signiﬁcant re-
ductions in LRP1 expression in aortic biopsies collected fromrMMP9 (20ng/mL)
AnƟ-LRP1 (30μg/mL)
Control IgG1 (30μg/mL)
- + + +
- - + -
- - - +
P = 0.270
Mean Diff. 95% CI Significance
MMP9 vs. MMP9 + Anti-LRP1 0.8863 -0.7122 - 2.485 NS
MMP9 vs. MMP9 + Control IgG1 0.7264 -0.8721 - 2.325 NS
MMP9 + Anti-LRP1 vs. MMP9 + Control IgG1 -0.1599 -1.758 - 1.439 NS
A
(24 h)
Figure 3. The effect of in vitro low-density lipoprotein receptor-related
(MMP9) activity. Vascular smooth muscle cells were cultured in the
antibodies, control IgG1, or vehicle. MMP9 activity in cell culture su
48 h after the addition of MMP9. Cells that did not receive MMP9
analyses. Mean  SEM MMP9 activity is shown for each group (n ¼ 3
via one-way analysis of variance; tables show mean differences and 95
NS ¼ nonsigniﬁcant. *p < .05 after correction via Tukey’s post-hoc tepatients with AAA compared with nonaneurysmal organ
donor controls.17 Using antibodies against a different LRP1
immunogen and an alternative house-keeping protein, it
was conﬁrmed in the present study that aortic LRP1 protein
expression was downregulated in Australian patients with
large AAA compared with nonaneurysmal controls. Collec-
tively, these ﬁndings suggest that LRP1 dysregulation is
localized to the aortic wall in patients with AAA. This was
assessed in vitro, and the present data suggest that LRP1
blockade signiﬁcantly impairs the ability of VSMC to remove
the AAA-relevant protease MMP9 from the surrounding
media.
Bown et al. suggested that the LRP1 rs1466535 CC ge-
notype is associated with increased LRP1 expression
(w1.2-fold) compared with the TT genotype.7 It should be
noted that Bown et al. analyzed ascending aortic biopsies,7
contrary to the IRA samples analyzed in the current study
and the previous investigation by Chan et al.17 Gene
expression patterns differ between aortic regions and work
is needed to assess whether the rs1466535 CC genotype is
associated with differential IRA LRP1 expression.27 Thus,
the mechanisms underpinning reduced IRA LRP1 expres-
sion in patients with AAA remain unclear. Chan et al. hy-
pothesized that LRP1 may be regulated by miR205.17 Kim
et al. demonstrated that aortic expression of miR205 is
signiﬁcantly increased in apolipoprotein E-deﬁcient mice,
which developed AAA in response to angiotensin II infu-
sion.28 Moreover, administration of anti-miR205 oligonu-
cleotides to aortic endothelial cells greatly attenuated
angiotensin II-induced AAA development. Kim et al. also
showed that LRP1 expression was markedly decreased in
response to angiotensin II infusion but was not rescued by
in vivo anti-miR205 administration, suggesting that miR205
may exert AAA protective effects through other path-
ways.28 Recent data also demonstrate that normocholes-
terolemic mice deﬁcient in smooth muscle LRP1 (smLRP1/
) are no more susceptible to angiotensin II-induced AAA0
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protein 1 (LRP1) blockade on extracellular matrix metalloprotease
presence of recombinant MMP9 after exposure to LRP1-blocking
pernatants was assessed via gelatin zymography (A) 24 and (B)
are included as negative controls but are not included in further
for all). MMP9 activity was assessed between experimental groups
% conﬁdence intervals (CI) for comparisons between groups. Note.
st for multiple comparisons.
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aneurysms within the ascending aorta and mesenteric ar-
tery was reported.29 It should be noted that normocho-
lesterolemic mice appear to be more resistant to
angiotensin II-induced AAA than dyslipidemic strains, and
future studies employing other AAA induction approaches
in these mice are needed to further assess the role of LRP1
in AAA formation.23,30,31
Although there is no direct evidence of a role for LRP1
in AAA formation, studies of the smLRPe/e mouse have
demonstrated an important role for this protein in
maintaining vascular integrity.14,16,32 smLRPe/e mice
aortas show Marfan syndrome-like phenotypes with
disruption of the elastic laminae and VSMC hyperplasia,
increased vessel tortuosity, thickness, and dilatation.14e
16,32 Comparable circulating cholesterol concentrations
in smLRP1/ and control mice suggest that the observed
pathologies are independent of lipoprotein metabolism.14
Intriguingly, mice deﬁcient in both smLRP1 and low-
density lipoprotein receptor (LDLR) appear more suscep-
tible to atherosclerosis than smLRP1þLDLRe/e controls
demonstrated by widespread lesion formation following
high cholesterol feeding.14,16,32 However, the aetiologies
of AAA and atherothrombosis appear distinct.20,33 AAA is
associated with VSMC apoptosis and extracellular matrix
degeneration, rather than cellular proliferation. MMP9,
an LRP1 ligand, is overexpressed in human and mouse
AAA biopsies, and is implicated in AAA pathogenesis.1,31
The current study suggests a role for LRP1 in regulating
aortic MMP9 concentrations evidenced by heightened
proteolytic activity in supernatants from LRP1-
compromised VSMC. This is supported by prior data
demonstrating increased MMP9 activity in conditioned
media harvested from mouse embryonic ﬁbroblasts
treated with an LRP1 antagonist, and an accumulation of
MMP9 within the aortas of smLRP1/ mice.14,34 These
ﬁndings suggest that aortic LRP1 dysregulation may
exacerbate extracellular matrix proteolysis, although LRP1
has the potential to contribute towards multiple AAA
pathogenic mechanisms owing to the broad spectrum of
ligands for this receptor.9
Extracellular forms of LRP1 are thought to result from
shedding of the LRP1 ectodomain.35e37 No association of
circulating LRP1 concentration with AAA was observed,
suggesting that low IRA LRP1 expression in patients with
AAA does not result from heightened extracellular shed-
ding. Immunohistochemistry data by Chan et al. demon-
strate that LRP1 is predominantly expressed within the
aortic media and adventitia, and conﬁrm that this is
reduced in human AAA, although the cells that express LRP1
in the normal aorta were not investigated. LRP1 is known to
be expressed by VSMC. Thus, it is possible that the loss of
VSMC typically demonstrated within the aortas of patients
with AAA may have contributed to the downregulation of
LRP1 observed in the current study.17 Further studies are
required to assess this directly.
There are several limitations to the current study. First,
the sample sizes employed in the Western blotting analyseswere relatively small. As most AAAs are now managed by
endovascular repair aortic wall biopsies can only be ob-
tained from the occasional patient undergoing open sur-
gery for a large AAA.1 Similarly, ethical and practical
considerations prevent the collection of aortic biopsies
from large numbers of control donors; however, sample
sizes here are similar to other published studies.17,22,38e40
Second, the organ donor controls were younger than the
patients with AAA, and the possibility that the age imbal-
ance may have contributed to differences in aortic LRP1
expression cannot be excluded. Limited clinical details were
available for the organ donor controls and variation in
cardiovascular risk factors between groups could not be
adjusted for. However, organ donors are often the only
viable source of healthy aortic biopsies.22,41 Some previous
studies have utilized macroscopically healthy tissues prox-
imal to the AAA sac as matched control tissues; however,
these were not available for the current study.24,38 A recent
genome-wide expression study comparing biopsies from
the proximal aneurysm neck with IRA biopsies from organ
donors demonstrated signiﬁcant reductions in LRP1
expression in patients with AAA.42 This suggests that LRP1
dysregulation precedes macroscopic AAA dilatation. Third,
no plasma samples were available from the patients with
AAA or organ donors who provided aortic biopsies. Thus,
IRA and plasma LRP1 concentrations could not be directly
compared in these individuals. Instead, plasma samples
were obtained from men with screen-detected AAAs, not
hospital-referred patients. Consequently most aneurysmal
blood donors had a small (<50 mm) AAA. A difference in
plasma LRP1 concentration may be seen when comparing
patients with large AAAs to healthy controls, although it
was not possible to assess this in the present study.
Furthermore, the ELISA used in the present study recog-
nizes an extracellular LRP1 immunogen, whereas the
Western blotting antibody employed is raised against an
intracellular epitope. This complicates direct comparison of
the two tests. Limited sample availability prevented the
assessment of aortic tissue extracts by ELISA in order to
cross-validate the assay. Moreover, it is possible that minor
differences in plasma LRP1 concentration between the
groups may have been masked by interassay variability
(reported as < 12%). Finally LRP1 genotype data were not
available for any participants in this study. The rationale for
assigning participants to experimental groups was there-
fore based on AAA presence.
In summary, plasma LRP1 concentrations were similar in
relatively large groups of community-dwelling men with and
without AAA (n ¼ 189 and n ¼ 309 respectively), mini-
mizing the biomarker potential for this molecule. The data
support an inverse association between IRA LRP1 expres-
sion and AAA presence, and suggest that LRP1 inhibition in
VSMC may potentially contribute to MMP9 accumulation
within the aortic wall. Studies employing larger biopsy
numbers and alternative methodologies, such as RNA
interference, are required to validate these ﬁndings, and to
further assess the impact of reduced LRP1 expression on
AAA pathology.
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